Littlewood A J, Russell J, Harvey G R, Hughes D E, Russell R G, Gowen M
Bath Institute for Rheumatic Diseases, University of Bath, United Kingdom.
Endocrinology. 1991 Sep;129(3):1513-20. doi: 10.1210/endo-129-3-1513.
Interleukin 6 (IL-6) probably plays a central role in the acute phase response and in haemopoiesis and may be involved in the control of bone turnover. We have studied the release of IL-6 from human trabecular bone cells treated with a variety of stimuli using a specific bioassay. In serum free medium, unstimulated human osteoblast-like cells produced IL-6 in the range of 1000-2050 pg/ml/24 h. Recombinant human interleukin 1 (IL-1 alpha) (10(-13)-10(-11) M), tumor necrosis factor alpha (TNF alpha) (10(-9)-10(-7) M) and lipopolysaccharide (5-500 ng/ml) all stimulated release of IL-6 from human bone cells. Maximal levels of 17,000 pg/ml were observed using the highest concentration of IL-1. 1,25(OH)2D3 and PTH did not stimulate IL-6 release. Using a specific sheep antihuman IL-6 antibody, all IL-6 activity could be neutralized. In parallel studies, ROS 17/2.8 rat osteosarcoma cells released around 50 pg/ml of IL-6 under basal conditions which were increased to a maximum of 900 pg/ml by treatment with PTH (10(-9) M). The cytokines were less effective and 1,25(OH)2D3 again had no effect. Modulation of expression of IL-6 mRNA in human osteoblast cells was examined using a human complementary deoxyribonucleic acid probe. The mRNA was constitutively expressed, and IL-1 (10(-11) M) and TNF (10(-7) M) induced further mRNA expression within 2 h, which was sustained over 24 h. 1,25(OH)2D3 (10(-7) M), IL-6 (2000 pg/ml), and PTH (10(-9) M) exerted no effects at any time point. Dexamethasone (10(-6) M) suppressed both basal and IL-1- and TNF-induced IL-6 mRNA expression. IL-6 receptor mRNA was constitutively expressed but was not regulated by any of the above agents. It is clear that rodent and human osteoblasts differ in their production of IL-6 and its modulation. These data support the hypothesis that IL-6 is produced locally in human bone by osteoblasts under the direction of other cytokines. This could have implications in bone remodeling, haemopoiesis, and systemic responses to local injury.
白细胞介素6(IL-6)可能在急性期反应和造血过程中起核心作用,并且可能参与骨转换的调控。我们使用特异性生物测定法研究了用多种刺激处理的人小梁骨细胞释放IL-6的情况。在无血清培养基中,未受刺激的人成骨样细胞产生的IL-6范围为1000 - 2050 pg/ml/24小时。重组人白细胞介素1(IL-1α)(10⁻¹³ - 10⁻¹¹ M)、肿瘤坏死因子α(TNFα)(10⁻⁹ - 10⁻⁷ M)和脂多糖(5 - 500 ng/ml)均刺激人骨细胞释放IL-6。使用最高浓度的IL-1时观察到最高水平为17,000 pg/ml。1,25(OH)₂D₃和甲状旁腺激素(PTH)未刺激IL-6释放。使用特异性羊抗人IL-6抗体,所有IL-6活性均可被中和。在平行研究中,ROS 17/2.8大鼠骨肉瘤细胞在基础条件下释放约50 pg/ml的IL-6,用PTH(10⁻⁹ M)处理后增加至最高900 pg/ml。细胞因子的作用较小,1,25(OH)₂D₃同样无作用。使用人互补脱氧核糖核酸探针检测人成骨细胞中IL-6 mRNA表达的调节情况。mRNA组成性表达,IL-1(10⁻¹¹ M)和TNF(10⁻⁷ M)在2小时内诱导进一步的mRNA表达,并持续24小时。1,25(OH)₂D₃(10⁻⁷ M)、IL-6(2000 pg/ml)和PTH(10⁻⁹ M)在任何时间点均无作用。地塞米松(10⁻⁶ M)抑制基础以及IL-1和TNF诱导的IL-6 mRNA表达。IL-6受体mRNA组成性表达,但不受上述任何一种试剂的调节。显然,啮齿动物和成骨细胞在IL-6的产生及其调节方面存在差异。这些数据支持以下假设:在其他细胞因子的指导下,人骨中的成骨细胞在局部产生IL-6。这可能对骨重塑、造血以及对局部损伤的全身反应产生影响。